Literature DB >> 32404955

Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.

Jean-Christophe Tille1, André F Vieira2,3,4, Caroline Saint-Martin5, Lounes Djerroudi2, Laëtitia Furhmann2, Francois-Clement Bidard6, Youlia Kirova7, Anne Tardivon8, Fabien Reyal9, Matthieu Carton5, Anne Vincent-Salomon10,11.   

Abstract

The prognostic impact of tumor-infiltrating lymphocytes (TILs) within invasive lobular carcinoma (ILC) remains to be better characterized. In estrogen receptor (ER)-negative invasive ductal carcinomas of no special type (IDC-NST), TILs are associated with good prognosis. The aim of this study was to examine TILs in ILC, with particular focus on prognostic and clinicopathologic features. A cohort comprising 459 consecutive ILCs diagnosed in a single institution from 2005 to 2008 met the eligibility criteria for this study. The percentage of tumor area occupied by TILs was quantified by two breast pathologists and categorized into three groups: no TILs, ≤5%, >5%. Clinicopathologic features were tested by Fisher's exact tests or Chi2 tests. Overall survival (OS) and invasive disease-free survival (iDFS) were estimated by Kaplan-Meier and Cox proportional hazard statistics. There were 239 TIL-negative cases, 185 cases with ≤5% TILs, and 35 cases with >5% TILs. TILs were associated with younger age, larger tumors, lymph node involvement, poor Nottingham prognostic index, HER2 amplification, multinucleation, and prominent nucleoli (p < 0.05). Poor OS was significantly associated with increasing TILs in the univariate Cox proportional hazards model (p < 0.001) and Kaplan-Meier estimator (p < 0.05, log-rank test). Similar results were observed for iDFS (p = 0.004 for Cox univariate and p = 0.005 for log-rank test). Notably, TILs can identify a subset of ILC patients with poor OS independently of molecular subtype and lymph node metastases (multivariate Cox, p < 0.001, OS hazard ratio (HR) = 4.38 and HR = 6.15, for ≤5% and >5% TILs, respectively, vs. absence of TILs). Prominent nucleoli was the only nuclear feature associated with poor OS (p = 0.05) and iDFS (p = 0.05) in univariate Cox survival analysis. TILs represent a promising new morphologic biomarker associated with poor outcome of ILC, in contrast with that observed in ER-negative IDC-NST.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32404955     DOI: 10.1038/s41379-020-0561-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  40 in total

Review 1.  Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Authors:  Séverine Guiu; Anita Wolfer; William Jacot; Pierre Fumoleau; Gilles Romieu; Franck Bonnetain; Maryse Fiche
Journal:  Crit Rev Oncol Hematol       Date:  2014-07-30       Impact factor: 6.312

2.  Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.

Authors:  Nadège Gruel; Carlo Lucchesi; Virginie Raynal; Manuel J Rodrigues; Gaëlle Pierron; Rémi Goudefroye; Paul Cottu; Fabien Reyal; Xavier Sastre-Garau; Alain Fourquet; Olivier Delattre; Anne Vincent-Salomon
Journal:  Eur J Cancer       Date:  2010-06-21       Impact factor: 9.162

3.  Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.

Authors:  M Tubiana-Hulin; D Stevens; S Lasry; J M Guinebretière; L Bouita; C Cohen-Solal; P Cherel; J Rouëssé
Journal:  Ann Oncol       Date:  2006-06-01       Impact factor: 32.976

4.  Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.

Authors:  Massimo Cristofanilli; Ana Gonzalez-Angulo; Nour Sneige; Shu-Wan Kau; Kristine Broglio; Richard L Theriault; Vicente Valero; Aman U Buzdar; Henry Kuerer; Thomas A Buchholz; Thomas A Buccholz; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

5.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Authors:  Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

6.  The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.

Authors:  T Korhonen; T Kuukasjärvi; H Huhtala; E L Alarmo; K Holli; A Kallioniemi; L Pylkkänen
Journal:  Breast       Date:  2013-07-14       Impact factor: 4.380

7.  The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.

Authors:  M-C Mathieu; R Rouzier; A Llombart-Cussac; L Sideris; S Koscielny; J P Travagli; G Contesso; S Delaloge; M Spielmann
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

Review 8.  Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems.

Authors:  Matthew J Sikora; Rachel C Jankowitz; David J Dabbs; Steffi Oesterreich
Journal:  Steroids       Date:  2012-11-21       Impact factor: 2.668

9.  Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.

Authors:  Yayoi Adachi; Junko Ishiguro; Haruru Kotani; Tomoka Hisada; Mari Ichikawa; Naomi Gondo; Akiyo Yoshimura; Naoto Kondo; Masaya Hattori; Masataka Sawaki; Takashi Fujita; Toyone Kikumori; Yasushi Yatabe; Yasuhiro Kodera; Hiroji Iwata
Journal:  BMC Cancer       Date:  2016-03-25       Impact factor: 4.430

10.  High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.

Authors:  M A Bollet; A Savignoni; J-Y Pierga; M Lae; V Fourchotte; Y M Kirova; R Dendale; F Campana; B Sigal-Zafrani; R Salmon; A Fourquet; A Vincent-Salomon
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

View more
  7 in total

1.  Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.

Authors:  Yu Zhang; Xiulan Luo; Min Chen; Libo Yang; Ting Lei; Tianjie Pu; Bing Wei; Hong Bu; Zhang Zhang
Journal:  Breast Cancer Res Treat       Date:  2022-06-06       Impact factor: 4.872

Review 2.  The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Authors:  Khalid El Bairi; Harry R Haynes; Elizabeth Blackley; Susan Fineberg; Jeffrey Shear; Sophia Turner; Juliana Ribeiro de Freitas; Daniel Sur; Luis Claudio Amendola; Masoumeh Gharib; Amine Kallala; Indu Arun; Farid Azmoudeh-Ardalan; Luciana Fujimoto; Luz F Sua; Shi-Wei Liu; Huang-Chun Lien; Pawan Kirtani; Marcelo Balancin; Hicham El Attar; Prerna Guleria; Wenxian Yang; Emad Shash; I-Chun Chen; Veronica Bautista; Jose Fernando Do Prado Moura; Bernardo L Rapoport; Carlos Castaneda; Eunice Spengler; Gabriela Acosta-Haab; Isabel Frahm; Joselyn Sanchez; Miluska Castillo; Najat Bouchmaa; Reena R Md Zin; Ruohong Shui; Timothy Onyuma; Wentao Yang; Zaheed Husain; Karen Willard-Gallo; An Coosemans; Edith A Perez; Elena Provenzano; Paula Gonzalez Ericsson; Eduardo Richardet; Ravi Mehrotra; Sandra Sarancone; Anna Ehinger; David L Rimm; John M S Bartlett; Giuseppe Viale; Carsten Denkert; Akira I Hida; Christos Sotiriou; Sibylle Loibl; Stephen M Hewitt; Sunil Badve; William Fraser Symmans; Rim S Kim; Giancarlo Pruneri; Shom Goel; Prudence A Francis; Gloria Inurrigarro; Rin Yamaguchi; Hernan Garcia-Rivello; Hugo Horlings; Said Afqir; Roberto Salgado; Sylvia Adams; Marleen Kok; Maria Vittoria Dieci; Stefan Michiels; Sandra Demaria; Sherene Loi
Journal:  NPJ Breast Cancer       Date:  2021-12-01

Review 3.  Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Authors:  Amy E McCart Reed; Lauren Kalinowski; Peter T Simpson; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

Review 4.  The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.

Authors:  Saeed Asiry; Gina Kim; Panagiota S Filippou; Luis Rivera Sanchez; David Entenberg; Douglas K Marks; Maja H Oktay; George S Karagiannis
Journal:  Front Immunol       Date:  2021-04-13       Impact factor: 7.561

5.  An Expandable Informatics Framework for Enhancing Central Cancer Registries with Digital Pathology Specimens, Computational Imaging Tools, and Advanced Mining Capabilities.

Authors:  David J Foran; Eric B Durbin; Wenjin Chen; Evita Sadimin; Ashish Sharma; Imon Banerjee; Tahsin Kurc; Nan Li; Antoinette M Stroup; Gerald Harris; Annie Gu; Maria Schymura; Rajarsi Gupta; Erich Bremer; Joseph Balsamo; Tammy DiPrima; Feiqiao Wang; Shahira Abousamra; Dimitris Samaras; Isaac Hands; Kevin Ward; Joel H Saltz
Journal:  J Pathol Inform       Date:  2022-01-05

6.  STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer.

Authors:  Jiale Sun; Xuedong Wei; Jiawei You; Wenchang Yue; Jun Ouyang; Zhixin Ling; Jianquan Hou
Journal:  Int J Gen Med       Date:  2021-09-11

7.  The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer.

Authors:  Carina Forsare; Sara Vistrand; Anna Ehinger; Kristina Lövgren; Lisa Rydén; Mårten Fernö; Ulrik Narbe
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.